CD274 and neoplasm: With a glimpse at the recent advances of tumour immunotherapy, the combination paradigms between conventional cancer-treatment modalities (e.g., RFA14, PDT49 and PTT50) with CTLA-4 or PD-1/PDL-1 could maximise benefits of cancer immunotherapies.